Literature DB >> 9627000

Single amino acid analogs of a myasthenogenic peptide modulate specific T cell responses and prevent the induction of experimental autoimmune myasthenia gravis.

Y Katz-Levy1, M Dayan, I Wirguin, M Fridkin, M Sela, E Mozes.   

Abstract

Peptide p259-271 of the human acetylcholine receptor alpha-subunit, preferentially stimulates T cells of patients with myasthenia gravis (MG) and is an immunodominant epitope for T cells of BALB/c mice. A p259-271 specific T cell line of BALB/c origin was established and was shown to induce experimental MG in naive mice. Seven analogs of p259-271 were synthesized, and two of them were found to inhibit the p259-271 specific proliferative responses of the line and of p259-271 primed lymph node cells. Moreover, the most efficient inhibitor, analog 262Lys, prevented the MG related manifestations in mice inoculated with the line, and might be of potential value for the treatment of MG.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9627000     DOI: 10.1016/s0165-5728(97)00265-8

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  7 in total

Review 1.  Peptide-based immunotherapy of autoimmunity: a path of puzzles, paradoxes and possibilities.

Authors:  S M Anderton
Journal:  Immunology       Date:  2001-12       Impact factor: 7.397

2.  Oral administration of a dual analog of two myasthenogenic T cell epitopes down-regulates experimental autoimmune myasthenia gravis in mice.

Authors:  M Paas-Rozner; M Dayan; Y Paas; J P Changeux; I Wirguin; M Sela; E Mozes
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-29       Impact factor: 11.205

3.  Suppression of myasthenogenic responses of a T cell line by a dual altered peptide ligand by induction of CD4+CD25+ regulatory cells.

Authors:  Badiga Venkata Aruna; Michael Sela; Edna Mozes
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-12       Impact factor: 11.205

4.  Altered peptide ligands act as partial agonists by inhibiting phospholipase C activity induced by myasthenogenic T cell epitopes.

Authors:  A Faber-Elmann; M Paas-Rozner; M Sela; E Mozes
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-24       Impact factor: 11.205

5.  The role of CD8+CD28 regulatory cells in suppressing myasthenia gravis-associated responses by a dual altered peptide ligand.

Authors:  Hava Ben-David; Amir Sharabi; Molly Dayan; Michael Sela; Edna Mozes
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-23       Impact factor: 11.205

6.  A dual altered peptide ligand down-regulates myasthenogenic T cell responses by up-regulating CD25- and CTLA-4-expressing CD4+ T cells.

Authors:  Miri Paas-Rozner; Michael Sela; Edna Mozes
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-12       Impact factor: 11.205

Review 7.  Therapeutic vaccines in autoimmunity.

Authors:  Michael Sela; Edna Mozes
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-12       Impact factor: 11.205

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.